| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab AM Menzies, DB Johnson, S Ramanujam, VG Atkinson, ANM Wong, ... Annals of Oncology 28 (2), 368-376, 2017 | 799 | 2017 |
| The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy ANM Wong, GA McArthur, MS Hofman, RJ Hicks European journal of nuclear medicine and molecular imaging 44 (Suppl 1), 67-77, 2017 | 131 | 2017 |
| Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases S Parakh, JJ Park, S Mendis, R Rai, W Xu, S Lo, M Drummond, C Rowe, ... British journal of cancer 116 (12), 1558-1563, 2017 | 110 | 2017 |
| The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma B Lee, A Wong, D Kee, P Neeson, M Shackleton, G McArthur, S Sandhu Annals of Oncology 27 (6), 1174-1177, 2016 | 65 | 2016 |
| Effectiveness of a clinical pathway for acute stroke care in a district general hospital: an audit WJ Taylor, A Wong, RJ Siegert, HK McNaughton BMC health services research 6, 1-7, 2006 | 60 | 2006 |
| 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma A Wong, J Callahan, M Keyaerts, B Neyns, J Mangana, S Aberle, ... Cancer Imaging 20, 1-12, 2020 | 50 | 2020 |
| Balancing the hype with reality: what do patients with advanced melanoma consider when making the decision to have immunotherapy? A Wong, A Billett, D Milne The oncologist 24 (11), e1190-e1196, 2019 | 32 | 2019 |
| Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death‐1 monoclonal antibodies for advanced melanoma A Wong, M Williams, D Milne, K Morris, P Lau, O Spruyt, S Fullerton, ... Asia‐Pacific Journal of Clinical Oncology 13 (6), 385-390, 2017 | 31 | 2017 |
| γδ T cells in merkel cell carcinomas have a proinflammatory profile prognostic of patient survival NA Gherardin, K Waldeck, A Caneborg, LG Martelotto, S Balachander, ... Cancer immunology research 9 (6), 612-623, 2021 | 26 | 2021 |
| Integration of immuno-oncology and palliative care A Wong, S Fullerton, O Spruyt, B Brady, G McArthur, S Sandhu J Clin Oncol 34 (13), 1561-1562, 2016 | 17 | 2016 |
| Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders (AD) or major toxicity with ipilimumab (IPI). AM Menzies, DB Johnson, S Ramanujam, V Atkinson, ANM Wong, ... Journal of Clinical Oncology 34 (15_suppl), 9515-9515, 2016 | 15 | 2016 |
| Risk factors for and timing of death of extremely preterm infants DE Elder, A Wong, JM Zuccollo Australian and New Zealand Journal of Obstetrics and Gynaecology 49 (4), 407-410, 2009 | 9 | 2009 |
| Spleen to liver ratio (SLR): Novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma. ANM Wong, J Callahan, J Beresford, A Herschtal, S Fullerton, D Milne, ... Journal of Clinical Oncology 34 (15_suppl), 9523-9523, 2016 | 7 | 2016 |
| Changes in cause of neonatal death over a decade A Wong, D Elder, J Zuccollo Clinical Correspondence, 2008 | 7 | 2008 |
| Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma. Asia Pac J Clin … A Wong, M Williams, D Milne, K Morris, P Lau, O Spruyt | 5 | |
| Pembrolizumab-induced myasthenia gravis: Literature review of ocular manifestations and a refractory case O Dugena, C Zheng, J Taylor, A Wong Journal of Immunotherapy 45 (6), 267-273, 2022 | 4 | 2022 |
| Outcomes of Australian patients receiving non‐funded anti‐PD‐1 immune checkpoint inhibitors for non‐melanoma cancers C Tiu, A Wong, A Herschtal, L Mileshkin Asia‐Pacific Journal of Clinical Oncology 14 (4), 337-342, 2018 | 3 | 2018 |
| Performance status as a predictor of response to anti-PD1 for metastatic melanoma A Wong, M Williams, D Milne, K Morris, P Lau, O Spruyt, S Fullerton, ... Asia–Pacific Journal of Clinical Oncology 12 (Suppl. 4), 71-71, 2016 | 3 | 2016 |
| Second-line immunotherapy in patients with metastatic melanoma A Wong, DE Gyorki The Lancet Oncology 22 (6), 746-748, 2021 | 2 | 2021 |
| Understanding real-world patients' experience on pembrolizumab, anti-programmed death 1 monoclonal antibody (anti-PD-1), for advanced melanoma: a qualitative study A Wong, A Billett, G McArthur, D Milne ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13, 148-148, 2017 | 1 | 2017 |
